0001209191-23-051898.txt : 20231004
0001209191-23-051898.hdr.sgml : 20231004
20231004160756
ACCESSION NUMBER: 0001209191-23-051898
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231004
DATE AS OF CHANGE: 20231004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eydelman Mikhail
CENTRAL INDEX KEY: 0001918033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 231307969
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, SUITE 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-02
0
0001649094
Vaxcyte, Inc.
PCVX
0001918033
Eydelman Mikhail
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300
SAN CARLOS
CA
94070
0
1
0
0
SVP, Gen Counsel & Corp Sec
1
Common Stock
2023-10-02
4
M
0
20000
21.41
A
40487
D
Common Stock
2023-10-02
4
S
0
7992
49.58
D
32495
D
Common Stock
2023-10-02
4
S
0
4874
50.22
D
27621
D
Common Stock
2023-10-02
4
S
0
7134
51.44
D
20487
D
Stock Option (right to buy)
21.41
2023-10-02
4
M
0
20000
0.00
A
2032-05-08
Common Stock
20000
205000
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $48.94 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $49.94 to $50.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $50.97 to $51.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact
2023-10-04